177 related articles for article (PubMed ID: 23113675)
1. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
Bouchet S; Titier K; Moore N; Lassalle R; Ambrosino B; Poulette S; Schuld P; Belanger C; Mahon FX; Molimard M
Fundam Clin Pharmacol; 2013 Dec; 27(6):690-7. PubMed ID: 23113675
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
[TBL] [Abstract][Full Text] [Related]
3. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V; Bouchet S; Widmer N; Schuld P; Decosterd LA; Buclin T; Mahon FX; Csajka C; Molimard M
Leuk Res; 2014 Jul; 38(7):764-72. PubMed ID: 24844604
[TBL] [Abstract][Full Text] [Related]
4. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of imatinib targeted delivery in human leukocytes.
Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
[TBL] [Abstract][Full Text] [Related]
7. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
[TBL] [Abstract][Full Text] [Related]
8. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
Racil Z; Razga F; Klamova H; Voglova J; Belohlavkova P; Malaskova L; Potesil D; Muzik J; Zackova D; Polakova KM; Zdrahal Z; Malakova J; Suttnar J; Dyr J; Mayer J
Hematol Oncol; 2014 Jun; 32(2):87-93. PubMed ID: 23963760
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits].
Bouchet S; Royer B; Le Guellec C; Titier K;
Therapie; 2010; 65(3):213-8. PubMed ID: 20699073
[TBL] [Abstract][Full Text] [Related]
10. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
11. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
[TBL] [Abstract][Full Text] [Related]
12. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Mahon FX; Molimard M
Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
[No Abstract] [Full Text] [Related]
13. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
14. Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
Awidi A; Ayed AO; Bsoul N; Magablah A; Mefleh R; Dweiri M; Ramahi M; Arafat E; Bishtawi M; Marie L
Leuk Res; 2010 Dec; 34(12):1573-5. PubMed ID: 20688395
[TBL] [Abstract][Full Text] [Related]
15. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
16. Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
Sharma SK; Kumar S; Vijayakumar AR; Seth T; Mishra P; Mahapatra M; Sazawal S; Velpandian T; Saxena R
J Cancer Res Ther; 2014; 10(2):305-8. PubMed ID: 25022382
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
18. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
19. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting.
Saleh MN; Haislip S; Sharpe J; Hess T; Gilmore J; Jackson J; Sail KR; Ericson SG; Chen L
Curr Med Res Opin; 2014 Apr; 30(4):529-36. PubMed ID: 24156689
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
